Recombinant Human Endostatin in Combination With XELOX Therapy in Patient With Advanced Colorectal Cancer.
Status:
Unknown status
Trial end date:
2021-08-01
Target enrollment:
Participant gender:
Summary
To study safety and efficacy of intravenous pump of recombinant human endostatin combined
with XELOX-treated and also investigate the potential value of CECs level for the prediction
of PD and outcomes in patients with advanced colorectal cancer.